Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

120.56USD
30 Sep 2016
Change (% chg)

$1.30 (+1.09%)
Prev Close
$119.26
Open
$119.66
Day's High
$121.08
Day's Low
$119.45
Volume
363,965
Avg. Vol
320,869
52-wk High
$121.70
52-wk Low
$69.25

EW.N

Chart for EW.N

About

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a... (more)

Overall

Beta: 0.56
Market Cap(Mil.): $25,664.67
Shares Outstanding(Mil.): 212.88
Dividend: --
Yield (%): --

Financials

  EW.N Industry Sector
P/E (TTM): 49.87 45.80 36.19
EPS (TTM): 2.42 -- --
ROI: 15.69 7.62 13.87
ROE: 22.20 9.66 14.78

FDA widens use of Edwards' devices for heart valve replacement

The U.S. Food and Drug Administration has widened the use of Edwards Lifesciences Corp's heart valves to patients at intermediate risk of complications if they underwent open heart surgery.

Aug 18 2016

FDA widens use of Edwards' devices for heart valve replacement

Aug 18 The U.S. Food and Drug Administration has widened the use of Edwards Lifesciences Corp's heart valves to patients at intermediate risk of complications if they underwent open heart surgery.

Aug 18 2016

BRIEF-EDWARDS INTUITY Elite Rapid Deployment Valve receives FDA approval

* Edwards INTUITY Elite Rapid Deployment Valve receives FDA approval Source text for Eikon: Further company coverage:

Aug 15 2016

BRIEF-Stantec signs letter of intent to acquire NYC-based Edwards & Zuck

* Stantec signs letter of intent to acquire NYC-based Edwards & Zuck: 120-person premiere buildings engineering firm Source text for Eikon: Further company coverage:

Aug 12 2016

BRIEF-Edwards Lifesciences gets pproval for Sapien 3 heart valve in Canada

* Edwards Lifesciences receives approval for sapien 3 heart valve in canada Source text for Eikon: Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

Jul 27 2016

UPDATE 2-Edwards Lifesciences lifts forecast on heart valve sales

July 26 Edwards Lifesciences Corp on Tuesday raised its full-year earnings forecast as quarterly profits beat estimates, and said U.S. regulators would soon likely approve its minimally invasive replacement heart valve for a broader range of patients.

Jul 26 2016

BRIEF-Edwards Lifesciences Q2 Adjusted EPS $0.76

* Sees Q3 Sales Between $720 Mln - $760 Mln; Sees Q3 Adjusted Earnings Per Share Between $0.62 - $0.68

Jul 26 2016

Edwards Lifesciences lifts forecast on heart valve sales momentum

Edwards Lifesciences Corp on Tuesday boosted its full-year earnings outlook after posting a stronger-than-expected quarterly profit and said it expected to soon gain U.S. approval to offer its minimally invasive replacement heart valve to a broader range of patients.

Jul 26 2016

Edwards Lifesciences lifts outlook on heart valve sales momentum

July 26 Edwards Lifesciences Corp on Tuesday boosted its full-year earnings outlook after posting a stronger-than-expected quarterly profit and said it expects to soon gain U.S. approval to offer its minimally invasive replacement heart valve to a broader range of patients.

Jul 26 2016

Edwards hits back at Boston Scientific in heart valve patent case

Medical device maker Edwards Lifesciences Corp has filed claims that rival Boston Scientific Corp's new heart valve replacement system, which is not yet for sale in the U.S., infringes several of Edwards' patents.

Jun 13 2016

Earnings vs. Estimates